Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 7/20 | 0.39 |
| ▸ | KYNU | Q16719 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282672 | 0.89 | APEX1 (0.42) | APEX1TTRNSD2HDAC3IDO1 | |
| SCHEMBL5595987 | 0.87 | APEX1 (0.41) | APEX1TTRNSD2KYNUHDAC3 | |
| Hydrochloric Acid SCHEMBL8172648 | 0.86 | APEX1 (0.40) | APEX1TTRNSD2HDAC3IDO1 | |
| SCHEMBL9177053 | 0.82 | TTR (0.46) | APEX1TTRNSD2HDAC3IDO1 | |
| SCHEMBL6046348 | 0.79 | CA2 (0.51) | APEX1TTRNSD2HDAC3IDO1 | |
| SCHEMBL1694943 | 0.77 | APEX1 (0.45) | APEX1TTRNSD2KYNUCA2 | |
| SCHEMBL292554 | 0.77 | CA2 (0.51) | APEX1CA2 | |
| SCHEMBL6867446 | 0.76 | APEX1 (0.55) | APEX1TTRNSD2HDAC3 | |
| SCHEMBL9178147 | 0.74 | TTR (0.58) | APEX1TTRNSD2 | |
| SCHEMBL111775 | 0.73 | HSD11B1 (0.53) | HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| WO-2025077996-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-04-17 | — | — | WO | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| EP-4419513-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2024-08-28 | — | — | EP | disclosed |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA (ES) | 2024-06-11 | — | — | US | disclosed |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| WO-2008153277-A1 | POLY(ORGANOPHOSPHAZENE) HYDROGELS FOR DRUG DELIVERY, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-12-18 | — | — | WO | disclosed |
| EP-2001513-A1 | THERMOSENSITIVE POLYPHOSPHAZENE-BIOACTIVE MOLECULE CONJUGATES, PREPARATION METHOD THEROF AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2008-12-17 | — | — | EP | disclosed |
| EP-1981544-A2 | BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE) HYDROGEL, PREPARATION METHOD THEREOF AND USE THEREOF | KIST Korea Institute of Science and Technology (KR) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007144423-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007114549-A1 | THERMOSENSITIVE POLYPHOSPHAZENE-BIOACTIVE MOLECULE CONJUGATES, PREPARATION METHOD THEROF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007083875-A2 | BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE) HYDROGEL, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-07-26 | — | — | WO | disclosed |
| US-20060173172-A1 | Method for producing novel spinosyn derivatives | JESCHKE PETER | 2006-08-03 | — | — | US | disclosed |
| US-7034130-B2 | Method for producing novel spinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2006-04-25 | — | — | US | disclosed |
| US-20040242858-A1 | Method for producing novel spinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384800-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | APEX1 2764/4885TTR 3764/4885NSD2 2900/4885 |
| US-20060173172-A1 | Method for producing novel spinosyn derivatives | COX15, SYVN1, CYP51A1 | APEX1 58/4885TTR 3699/4885NSD2 2066/4885 |
| US-20040242858-A1 | Method for producing novel spinosyn derivatives | COX15, SYVN1, CYP51A1 | APEX1 58/4885TTR 3699/4885NSD2 2066/4885 |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | MCL1, XPOT, GZMB | APEX1 1359/4885TTR 3219/4885NSD2 2282/4885 |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | APEX1 2764/4885TTR 3764/4885NSD2 2900/4885 |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | UGT1A3, UGT1A1, UGT1A6 | APEX1 2136/4885TTR 3523/4885NSD2 1188/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | APEX1 2133/4885TTR 4422/4885NSD2 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.